Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Summary

To assess the objective response rate (ORR: complete response + partial response \[CR+ PR\]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .

Timeline

Start

2010-03

Primary completion

2012-05

Completion

2015-10

Drugs

Indications